JP7167155B2 - ドーパミン-β-ヒドロキシラーゼ阻害剤 - Google Patents

ドーパミン-β-ヒドロキシラーゼ阻害剤 Download PDF

Info

Publication number
JP7167155B2
JP7167155B2 JP2020530502A JP2020530502A JP7167155B2 JP 7167155 B2 JP7167155 B2 JP 7167155B2 JP 2020530502 A JP2020530502 A JP 2020530502A JP 2020530502 A JP2020530502 A JP 2020530502A JP 7167155 B2 JP7167155 B2 JP 7167155B2
Authority
JP
Japan
Prior art keywords
methyl
pyrrolo
thioxo
imidazol
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020530502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505568A5 (https=
JP2021505568A (ja
Inventor
ラースロー、エルノ、キス
アレクサンダー、ベリャーエフ
ティノ、ロッシ
ペドロ、ヌーノ、レアル、パルマ
パトリシオ、マヌエル、ビエイラ、アラウホ、ソアレス、ダ、シルバ
ルイ、ピント
フランシスコ、カルドナ
Original Assignee
ビアル-ポルテラ エ コンパニア,ソシエダッド アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1720189.8A external-priority patent/GB201720189D0/en
Priority claimed from GBGB1804439.6A external-priority patent/GB201804439D0/en
Application filed by ビアル-ポルテラ エ コンパニア,ソシエダッド アノニマ filed Critical ビアル-ポルテラ エ コンパニア,ソシエダッド アノニマ
Publication of JP2021505568A publication Critical patent/JP2021505568A/ja
Publication of JP2021505568A5 publication Critical patent/JP2021505568A5/ja
Application granted granted Critical
Publication of JP7167155B2 publication Critical patent/JP7167155B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020530502A 2017-12-04 2018-11-30 ドーパミン-β-ヒドロキシラーゼ阻害剤 Active JP7167155B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1720189.8 2017-12-04
GBGB1720189.8A GB201720189D0 (en) 2017-12-04 2017-12-04 Dopamine-B-hydroxylase inhibitors
GB1804439.6 2018-03-20
GBGB1804439.6A GB201804439D0 (en) 2018-03-20 2018-03-20 Dopamin-b-hydroxylase inhibitors
PCT/PT2018/050043 WO2019112457A1 (en) 2017-12-04 2018-11-30 Dopamine-β-hydroxylase inhibitors

Publications (3)

Publication Number Publication Date
JP2021505568A JP2021505568A (ja) 2021-02-18
JP2021505568A5 JP2021505568A5 (https=) 2022-01-11
JP7167155B2 true JP7167155B2 (ja) 2022-11-08

Family

ID=65012066

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020530502A Active JP7167155B2 (ja) 2017-12-04 2018-11-30 ドーパミン-β-ヒドロキシラーゼ阻害剤

Country Status (16)

Country Link
US (2) US11434242B2 (https=)
EP (1) EP3720856A1 (https=)
JP (1) JP7167155B2 (https=)
KR (1) KR20200096584A (https=)
CN (1) CN111479812A (https=)
AU (1) AU2018379646A1 (https=)
BR (1) BR112020010216A2 (https=)
CA (1) CA3082337A1 (https=)
CL (1) CL2020001461A1 (https=)
IL (1) IL274550B2 (https=)
MX (1) MX2020005864A (https=)
PH (1) PH12020500542A1 (https=)
RU (1) RU2020121820A (https=)
SG (1) SG11202004231YA (https=)
TW (1) TW201925193A (https=)
WO (1) WO2019112457A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111479812A (zh) 2017-12-04 2020-07-31 巴尔-波特拉及康邦亚股份有限公司 多巴胺-b-羟化酶抑制剂
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
US20250122171A1 (en) * 2023-09-20 2025-04-17 Deep Apple Therapeutics, Inc. Substituted Amine Compounds, Compositions and Methods of Use
CN120383599A (zh) * 2024-01-29 2025-07-29 上海深势唯思科技有限责任公司 芳基杂环类Kv1.3抑制剂及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536103A (ja) 2001-05-24 2004-12-02 イスム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ 大学 オブ エルサレム ヒトのアセチルコリンエステラーゼ(ache)に対するアンチセンスオリゴヌクレオチド及びその使用
JP2006507261A (ja) 2002-10-11 2006-03-02 ポルテラ・アンド・シーエー・エスエー ドーパミン−ベータ−ヒドロキシラーゼの末梢選択的阻害剤としてのイミダゾール誘導体、及びこれらの用途
JP2010526136A (ja) 2007-05-08 2010-07-29 バイアル−ポルテラ アンド シーエー,エス.エー. ドーパミン−β−ヒドロキシラーゼの阻害剤としての1,3−ジヒドロイミダゾール−2−チオン誘導体
JP2019529460A (ja) 2016-09-23 2019-10-17 ビアル−ポルテラ エ コンパニア,ソシエダッド アノニマ 血管脳関門透過剤ドーパミン−b−ヒドロキシラーゼ阻害剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647790A (en) 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
FR2449689A1 (fr) 1979-02-20 1980-09-19 Logeais Labor Jacques Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique
US4628059A (en) 1985-10-31 1986-12-09 Smithklein Beckman Corporation Dopamine-β-hydroxylase inhibitors
WO1995029165A2 (en) 1994-04-26 1995-11-02 Syntex (U.S.A.) Inc. Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors
US6482982B1 (en) 2001-03-09 2002-11-19 University Of Sciences Of Philadelphia Halogenated antituberculosis agents
WO2008085008A1 (en) 2007-01-11 2008-07-17 Mogam Biotechnology Research Institute T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases
JP2010534676A (ja) 2007-07-23 2010-11-11 シノシア・セラピューティクス 心的外傷後ストレス障害の治療
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2014127350A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
CN111479812A (zh) 2017-12-04 2020-07-31 巴尔-波特拉及康邦亚股份有限公司 多巴胺-b-羟化酶抑制剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536103A (ja) 2001-05-24 2004-12-02 イスム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ 大学 オブ エルサレム ヒトのアセチルコリンエステラーゼ(ache)に対するアンチセンスオリゴヌクレオチド及びその使用
JP2006507261A (ja) 2002-10-11 2006-03-02 ポルテラ・アンド・シーエー・エスエー ドーパミン−ベータ−ヒドロキシラーゼの末梢選択的阻害剤としてのイミダゾール誘導体、及びこれらの用途
JP2010526136A (ja) 2007-05-08 2010-07-29 バイアル−ポルテラ アンド シーエー,エス.エー. ドーパミン−β−ヒドロキシラーゼの阻害剤としての1,3−ジヒドロイミダゾール−2−チオン誘導体
JP2019529460A (ja) 2016-09-23 2019-10-17 ビアル−ポルテラ エ コンパニア,ソシエダッド アノニマ 血管脳関門透過剤ドーパミン−b−ヒドロキシラーゼ阻害剤
JP2019529459A (ja) 2016-09-23 2019-10-17 ビアル−ポルテラ エ コンパニア,ソシエダッド アノニマ ドーパミン−b−ヒドロキシラーゼ阻害剤

Also Published As

Publication number Publication date
IL274550B2 (en) 2023-06-01
US11434242B2 (en) 2022-09-06
WO2019112457A1 (en) 2019-06-13
TW201925193A (zh) 2019-07-01
CN111479812A (zh) 2020-07-31
IL274550A (en) 2020-06-30
MX2020005864A (es) 2020-09-09
PH12020500542A1 (en) 2021-01-25
US20210171528A1 (en) 2021-06-10
SG11202004231YA (en) 2020-06-29
KR20200096584A (ko) 2020-08-12
BR112020010216A2 (pt) 2020-09-15
JP2021505568A (ja) 2021-02-18
CA3082337A1 (en) 2019-06-13
CL2020001461A1 (es) 2020-10-16
AU2018379646A1 (en) 2020-06-11
US20230138795A1 (en) 2023-05-04
RU2020121820A (ru) 2022-01-10
EP3720856A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
CN111601799B (zh) 作为Il-17调节剂的稠合咪唑衍生物
EP3692028B1 (en) Inhibiting ubiquitin specific peptidase 30
JP2026509484A (ja) Krasモジュレーターおよびその使用
US20190135799A1 (en) Heterocyclic compound
AU2012258618B2 (en) Metabotropic glutamate receptors 5 modulators and methods of use thereof
CN104725359B (zh) 取代的哌嗪化合物及其使用方法和用途
JP7167155B2 (ja) ドーパミン-β-ヒドロキシラーゼ阻害剤
AU2012258618A1 (en) Metabotropic glutamate receptors 5 modulators and methods of use thereof
EP4423068B1 (en) Rxfp1 agonists
SG175333A1 (en) Isoxazole-pyrazole derivatives
KR20170129729A (ko) 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체
AU2021268223B2 (en) Compound having KDM5 inhibitory activity and pharmaceutical use thereof
AU2018230236A1 (en) Novel imidazo[4,5-c]quinoline derivatives as LRRK2 inhibitors
TW201817728A (zh) 多巴胺-β-羥化酶抑制劑
JP2023548169A (ja) 統合的ストレス経路の調節剤
WO2015125785A1 (ja) 複数置換基を有するピラゾロン誘導体
WO2025015269A1 (en) Compounds, compositions, and methods
CN100381446C (zh) 氨基甲基取代的噻唑并苯并咪唑衍生物
CA3142348A1 (en) Dopamine-b-hydroxylase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221026

R150 Certificate of patent or registration of utility model

Ref document number: 7167155

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150